

After Prostate Cancer: A What-Comes-Next Guide to a Safe and Informed Recovery - Paperback
Pay over time for orders over $35.00 with
Men who have completed prostate cancer treatment often find themselves facing new challenges and setbacks that do not necessarily recede along with the cancer. Many books endeavor to explain the different types of prostate cancer treatments, but most conclude once a treatment choice has been made, offering readers little in the way of guidance through the challenges of the post-treatment period. After Prostate Cancer: A What-Comes-Next Guide to a Safe and Informed Recovery picks up where those books leave off. Dr. Arnold Melman, Chair of the Department of Urology at the Albert Einstein College of Medicine, offers a thorough description of what the prostate cancer recovery process is like and what readers can do to move themselves through recovery to the best possible health and long-term prognosis. Giving detailed explanations of what to expect and why based on diagnosis, treatment methodology, and other variables that make each man's post-treatment experience different, Dr. Melman offers strategies for mindfully and healthfully approaching post therapy issues, including confronting PSA measurement, erectile dysfunction, urinary incontinence and psychological issues that are a common result of living through prostate cancer and treatment. Sharing the experiences of other prostate cancer patients in addition to accessible explanations of the available medical literature, Dr. Melman helps readers and their partners to get the best information, make the most informed decisions, feel comfortable with those decisions, and work through issues as they arise. Treatment is only the beginning of getting back to a healthy life after a diagnosis. After Prostate Cancer offers the best information to help readers with everything that comes next.
In 1997 Dr. Melman was the president for the Society for the Study of Impotence. He's the Principal Investigator on an NIH grant designed to evaluate basic mechanisms of erectile physiology and was co-editor of the International Journal of Impotence Research. Dr. Melman is the past chairman of the FDA's Gastroenterology and Urology devices panel and is currently a voting member of the panel. He has been a reviewer at the National Institute of Health's Study Section for Urology grants for the past two years. Dr. Melman is the Principal Investigator on several clinical trials of new medications and treatment modalities. He has been granted patents on several new urological devices. Dr. Melman is a co-developer of the use of gene transfer for the therapy of smooth muscle diseases of the genito urinary systems.
In addition, Dr. Melman, along with Dr. George J. Christ, Ph.D., is a directing member of Ion Channel Innovations [http: //www.ionchannelinnovations.com/], a development stage biotechnology company formed to develop Ion Channel Therapy (ICT), an innovative gene transfer solution expected to be safe and effective for the long-term treatment of erectile dysfunction (ED), urinary incontinence (UI, urinary urgency, frequency and incontinence related to overactive bladder (OAB)), and potentially other smooth muscle diseases. Rosemary Newnham is a medical writer with a background in oral history and narrative medicine. A graduate of the non-fiction writing MFA program at Columbia University, Ms. Newnham has taught writing and literature to junior high students, ESL students, and medical students. She currently co-facilitates a creative writing workshop on the oncology unit of New York-Presbyterian Hospital. Previously, Ms. Newnham served as the publications manager for Survivors of the Shoah Visual History Foundation (a non-profit that collected and catalogued interviews with Holocaust survivors) and as Assistant Director of the Columbia University Oral History Research Office, where she managed the processing of hundreds of interviews from the September 11th Narrative and Memory Project.
Contributor(s)
Author
Free shipping on orders over $75. Standard shipping takes 3-7 business days. Returns accepted within 30 days of purchase.
Men who have completed prostate cancer treatment often find themselves facing new challenges and setbacks that do not necessarily recede along with the cancer. Many books endeavor to explain the different types of prostate cancer treatments, but most conclude once a treatment choice has been made, offering readers little in the way of guidance through the challenges of the post-treatment period. After Prostate Cancer: A What-Comes-Next Guide to a Safe and Informed Recovery picks up where those books leave off. Dr. Arnold Melman, Chair of the Department of Urology at the Albert Einstein College of Medicine, offers a thorough description of what the prostate cancer recovery process is like and what readers can do to move themselves through recovery to the best possible health and long-term prognosis. Giving detailed explanations of what to expect and why based on diagnosis, treatment methodology, and other variables that make each man's post-treatment experience different, Dr. Melman offers strategies for mindfully and healthfully approaching post therapy issues, including confronting PSA measurement, erectile dysfunction, urinary incontinence and psychological issues that are a common result of living through prostate cancer and treatment. Sharing the experiences of other prostate cancer patients in addition to accessible explanations of the available medical literature, Dr. Melman helps readers and their partners to get the best information, make the most informed decisions, feel comfortable with those decisions, and work through issues as they arise. Treatment is only the beginning of getting back to a healthy life after a diagnosis. After Prostate Cancer offers the best information to help readers with everything that comes next.
In 1997 Dr. Melman was the president for the Society for the Study of Impotence. He's the Principal Investigator on an NIH grant designed to evaluate basic mechanisms of erectile physiology and was co-editor of the International Journal of Impotence Research. Dr. Melman is the past chairman of the FDA's Gastroenterology and Urology devices panel and is currently a voting member of the panel. He has been a reviewer at the National Institute of Health's Study Section for Urology grants for the past two years. Dr. Melman is the Principal Investigator on several clinical trials of new medications and treatment modalities. He has been granted patents on several new urological devices. Dr. Melman is a co-developer of the use of gene transfer for the therapy of smooth muscle diseases of the genito urinary systems.
In addition, Dr. Melman, along with Dr. George J. Christ, Ph.D., is a directing member of Ion Channel Innovations [http: //www.ionchannelinnovations.com/], a development stage biotechnology company formed to develop Ion Channel Therapy (ICT), an innovative gene transfer solution expected to be safe and effective for the long-term treatment of erectile dysfunction (ED), urinary incontinence (UI, urinary urgency, frequency and incontinence related to overactive bladder (OAB)), and potentially other smooth muscle diseases. Rosemary Newnham is a medical writer with a background in oral history and narrative medicine. A graduate of the non-fiction writing MFA program at Columbia University, Ms. Newnham has taught writing and literature to junior high students, ESL students, and medical students. She currently co-facilitates a creative writing workshop on the oncology unit of New York-Presbyterian Hospital. Previously, Ms. Newnham served as the publications manager for Survivors of the Shoah Visual History Foundation (a non-profit that collected and catalogued interviews with Holocaust survivors) and as Assistant Director of the Columbia University Oral History Research Office, where she managed the processing of hundreds of interviews from the September 11th Narrative and Memory Project.
Contributor(s)
Author
